Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open Label, Multicenter, Platform Trial to Assess the Safety, Tolerability, and Efficacy of Inebilizumab and Blinatumomab in Subjects With Autoimmune Diseases

NCT06570798 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT06570798
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06570798 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open Label, Multicenter, Platform Trial to Assess the Safety, Tolerability, and Efficacy of Inebilizumab and Blinatumomab in Subjects With Autoimmune Diseases
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Recruiting
Start date
July 16, 2025
Completion date
August 6, 2028
Enrollment
220 (estimated)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

active refractory rheumatoid arthritis, systemic lupus erythematosus